ARCA biopharma Inc
For the period ended Dec 31, 2023. Filed Feb 1, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 1, 2024
ORKA$104.56+1.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
STATEMENTS OF CASH FLOWS
| Years Ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| (in thousands) | ||
| Cash flows from operating activities: | ||
| Net loss | $(5,339) | $(9,926) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation | 15 | 20 |
| Amortization of right-of-use asset - operating | 96 | 94 |
| Share-based compensation | 686 | 556 |
| Loss from disposal of property and equipment | — | 5 |
| Change in operating assets and liabilities: | ||
| Other current assets | 93 | 808 |
| Other assets | 6 | — |
| Accounts payable | 28 | (783) |
| Accrued compensation and employee benefits | (73) | (752) |
| Accrued expenses and other liabilities | (526) | (934) |
| Net cash used in operating activities | (5,014) | (10,912) |
| Cash flows from investing activities: | ||
| Purchase of property and equipment | — | (2) |
| Net cash used in investing activities | — | (2) |
| Cash flows from financing activities: | ||
| Net cash provided by financing activities | — | — |
| Net decrease in cash and cash equivalents | (5,014) | (10,914) |
| Cash and cash equivalents, beginning of year | 42,445 | 53,359 |
| Cash and cash equivalents, end of year | $37,431 | $42,445 |
| Supplemental cash flow information: | ||
| Interest paid | $— | $— |
| Income tax refund received | $— | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.